Skip to content
2000
Volume 4, Issue 1
  • ISSN: 2210-299X
  • E-ISSN: 2210-3007
file format pdf download PDF
file format text download EPUB
side by side viewer icon HTML

Abstract

Recent advances in the diagnosis and treatment of Hepatocellular Carcinoma (HCC) are transforming patient care. Progress in imaging modalities such as MRI, CT, and contrast-enhanced ultrasound, coupled with molecular diagnostics including liquid biopsy and next-generation sequencing, has significantly improved early detection and tumour characterization. Artificial intelligence and radiomics models are further enhancing the interpretation of imaging and the prediction of treatment outcomes.

Therapeutic strategies have expanded beyond traditional surgery, transplantation, and locoregional therapies to include systemic medicines. Notably, immune checkpoint inhibitors (., pembrolizumab, nivolumab), tyrosine kinase inhibitors (., lenvatinib, sorafenib), and combination regimens such as atezolizumab plus bevacizumab have demonstrated improved survival and quality of life in patients with advanced or metastatic HCC. Nanotechnology-based drug delivery and novel biomarkers are opening new avenues for precision medicine.

Despite these advances, challenges remain in sequencing therapies, overcoming treatment resistance, reducing recurrence, and ensuring equitable access worldwide. Personalized medicine guided by genomic and molecular profiling holds promise for tailoring treatment to tumour biology. Continuous innovation, multidisciplinary collaboration, and biomarker-driven clinical trials will be essential to shape the next generation of HCC management and improve long-term outcomes.

© 2026 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cis/10.2174/012210299X413855251206110649
2025-12-29
2026-03-08

  • From This Site

    /content/journals/cis/10.2174/012210299X413855251206110649
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cis/4/1/CIS-4-E2210299X413855.html?itemId=/content/journals/cis/10.2174/012210299X413855251206110649&mimeType=html&fmt=ahah

References

  1. SankarK. GongJ. OsipovA. MilesS.A. KosariK. NissenN.N. HendifarA.E. KoltsovaE.K. YangJ.D. Recent advances in the management of hepatocellular carcinoma.Clin. Mol. Hepatol.202330111510.3350/cmh.2023.012537482076
     [Google Scholar]
  2. WuK.T. WangC.C. LuL.G. ZhangW.D. ZhangF.J. ShiF. LiC.X. Hepatocellular carcinoma: Clinical study of long-term survival and choice of treatment modalities.World J. Gastroenterol.201319233649365710.3748/wjg.v19.i23.364923801868
     [Google Scholar]
  3. OmarM.A. OmranM.M. FaridK. TabllA.A. ShaheinY.E. EmranT.M. PetrovicA. LucicN.R. SmolicR. KovacT. SmolicM. Biomarkers for hepatocellular carcinoma: From origin to clinical diagnosis.Biomedicines2023117185210.3390/biomedicines1107185237509493
     [Google Scholar]
  4. ChanY.T. ZhangC. WuJ. LuP. XuL. YuanH. FengY. ChenZ.S. WangN. Biomarkers for diagnosis and therapeutic options in hepatocellular carcinoma.Mol. Cancer202423118910.1186/s12943‑024‑02101‑z39242496
     [Google Scholar]
  5. WangW. WeiC. Advances in the early diagnosis of hepatocellular carcinoma.Genes Dis.20207330831910.1016/j.gendis.2020.01.01432884985
     [Google Scholar]
  6. NaultJ.C. GalleP.R. MarquardtJ.U. The role of molecular enrichment on future therapies in hepatocellular carcinoma.J. Hepatol.201869123724710.1016/j.jhep.2018.02.01629505843
     [Google Scholar]
  7. ChengA.L. KangY.K. ChenZ. TsaoC.J. QinS. KimJ.S. LuoR. FengJ. YeS. YangT.S. XuJ. SunY. LiangH. LiuJ. WangJ. TakW.Y. PanH. BurockK. ZouJ. VoliotisD. GuanZ. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial.Lancet Oncol.2009101253410.1016/S1470‑2045(08)70285‑719095497
     [Google Scholar]
  8. ZenderL. VillanuevaA. TovarV. SiaD. ChiangD.Y. LlovetJ.M. Cancer gene discovery in hepatocellular carcinoma.J. Hepatol.201052692192910.1016/j.jhep.2009.12.03420385424
     [Google Scholar]
  9. MarquardtJ.U. GalleP.R. TeufelA. Molecular diagnosis and therapy of hepatocellular carcinoma (HCC): An emerging field for advanced technologies.J. Hepatol.201256126727510.1016/j.jhep.2011.07.00721782758
     [Google Scholar]
  10. SantoroA. RimassaL. BorbathI. DanieleB. SalvagniS. Van LaethemJ.L. Van VlierbergheH. TrojanJ. KolligsF.T. WeissA. MilesS. GasbarriniA. LencioniM. CicaleseL. ShermanM. GridelliC. BuggischP. GerkenG. SchmidR.M. BoniC. PersoneniN. HassounZ. AbbadessaG. SchwartzB. Von RoemelingR. LamarM.E. ChenY. PortaC. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: A randomised, placebo-controlled phase 2 study.Lancet Oncol.2013141556310.1016/S1470‑2045(12)70490‑423182627
     [Google Scholar]
  11. CallesA. KwiatkowskiN. CammarataB.K. ErcanD. GrayN.S. JänneP.A. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non‐small‐cell lung cancer cell lines.Mol. Oncol.20159126026910.1016/j.molonc.2014.08.01125226813
     [Google Scholar]
  12. GiordanoS. ColumbanoA. Met as a therapeutic target in HCC: Facts and hopes.J. Hepatol.201460244245210.1016/j.jhep.2013.09.00924045150
     [Google Scholar]
  13. ZhuA.X. ParkJ.O. RyooB.Y. YenC.J. PoonR. PastorelliD. BlancJ.F. ChungH.C. BaronA.D. PfifferT.E.F. OkusakaT. KubackovaK. TrojanJ. SastreJ. ChauI. ChangS.C. AbadaP.B. YangL. SchwartzJ.D. KudoM. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial.Lancet Oncol.201516785987010.1016/S1470‑2045(15)00050‑926095784
     [Google Scholar]
  14. AddissoukyT. A. Latest advances in hepatocellular carcinoma management and prevention through advanced technologies.Egypt Liver J202414110.1186/s43066‑023‑00306‑3
     [Google Scholar]
  15. Escutia-GutiérrezR. Sandoval-RodríguezA. Zamudio-OjedaA. Guevara-MartínezS.J. Armendáriz-BorundaJ. Advances of nanotechnology in the diagnosis and treatment of hepatocellular carcinoma.J. Clin. Med.20231221686710.3390/jcm1221686737959332
     [Google Scholar]
  16. AquinoI.M.C. PascutD. Liquid biopsy: New opportunities for precision medicine in hepatocellular carcinoma care.Ann. Hepatol.202429210117610.1016/j.aohep.2023.10117637972709
     [Google Scholar]
  17. LlovetJ.M. Zucman-RossiJ. PikarskyE. SangroB. SchwartzM. ShermanM. GoresG. Hepatocellular carcinoma.Nat. Rev. Dis. Primers2016211601810.1038/nrdp.2016.1827158749
     [Google Scholar]
  18. PascualS. HerreraI. IrurzunJ. New advances in hepatocellular carcinoma.World J. Hepatol.20168942143810.4254/wjh.v8.i9.42127028578
     [Google Scholar]
  19. YuB. MaW. Biomarker discovery in hepatocellular carcinoma (HCC) for personalized treatment and enhanced prognosis.Cytokine Growth Factor Rev.202479293810.1016/j.cytogfr.2024.08.00639191624
     [Google Scholar]
  20. WuX. LokkenR.P. MehtaN. Optimal treatment for small HCC (<3 cm): Resection, liver transplantation, or locoregional therapy?JHEP Reports20235810078110.1016/j.jhepr.2023.10078137456674
     [Google Scholar]
  21. LeeJ.J.X. TaiD.W.M. ChooS.P. Locoregional therapy in hepatocellular carcinoma: When to start and when to stop and when to revisit.ESMO Open20216310012910.1016/j.esmoop.2021.10012933887687
     [Google Scholar]
  22. ShihT.C. WangL. WangH.C. WanY.J.Y. Glypican-3: A molecular marker for the detection and treatment of hepatocellular carcinoma.Liver Res.20204416817210.1016/j.livres.2020.11.00333384879
     [Google Scholar]
  23. WangM.-D. DiaoY.-K. YaoL.-Q. FanZ.-Q. WangK.-C. WuH. GuL.-H. XuJ.-H. LiC. LvG.-Y. YangT. Emerging Role of Molecular Diagnosis and Personalized Therapy for Hepatocellular Carcinoma.iLIVER20243110008310.1016/j.iliver.2024.100083
     [Google Scholar]
  24. AllyA. BalasundaramM. CarlsenR. ChuahE. ClarkeA. DhallaN. HoltR.A. JonesS.J.M. LeeD. MaY. MarraM.A. MayoM. MooreR.A. MungallA.J. ScheinJ.E. SipahimalaniP. TamA. ThiessenN. CheungD. WongT. BrooksD. RobertsonA.G. BowlbyR. MungallK. SadeghiS. XiL. CovingtonK. ShinbrotE. WheelerD.A. GibbsR.A. DonehowerL.A. WangL. BowenJ. Gastier-FosterJ.M. GerkenM. HelselC. LeraasK.M. LichtenbergT.M. RamirezN.C. WiseL. ZmudaE. GabrielS.B. MeyersonM. CibulskisC. MurrayB.A. ShihJ. BeroukhimR. CherniackA.D. SchumacherS.E. SaksenaG. PedamalluC.S. ChinL. GetzG. NobleM. ZhangH. HeimanD. ChoJ. GehlenborgN. SaksenaG. VoetD. LinP. FrazerS. DefreitasT. MeierS. LawrenceM. KimJ. CreightonC.J. MuznyD. DoddapaneniH.V. HuJ. WangM. MortonD. KorchinaV. HanY. DinhH. LewisL. BellairM. LiuX. SantibanezJ. GlennR. LeeS. HaleW. ParkerJ.S. WilkersonM.D. HayesD.N. ReynoldsS.M. ShmulevichI. ZhangW. LiuY. IypeL. MakhloufH. TorbensonM.S. KakarS. YehM.M. JainD. KleinerD.E. JainD. DhanasekaranR. El-SeragH.B. YimS.Y. WeinsteinJ.N. MishraL. ZhangJ. AkbaniR. LingS. JuZ. SuX. HegdeA.M. MillsG.B. LuY. ChenJ. LeeJ-S. SohnB.H. ShimJ.J. TongP. AburataniH. YamamotoS. TatsunoK. LiW. XiaZ. StranskyN. SeiserE. InnocentiF. GaoJ. KundraR. ZhangH. HeinsZ. OchoaA. SanderC. LadanyiM. ShenR. AroraA. Sanchez-VegaF. SchultzN. KasaianK. RadenbaughA. BissigK-D. MooreD.D. TotokiY. NakamuraH. ShibataT. YauC. GraimK. StuartJ. HausslerD. SlagleB.L. OjesinaA.I. KatsonisP. KoireA. LichtargeO. HsuT-K. FergusonM.L. DemchokJ.A. FelauI. ShethM. TarnuzzerR. WangZ. YangL. ZenklusenJ.C. ZhangJ. HutterC.M. SofiaH.J. VerhaakR.G.W. ZhengS. LangF. ChudamaniS. LiuJ. LollaL. WuY. NareshR. PihlT. SunC. WanY. BenzC. PerouA.H. ThorneL.B. BoiceL. HuangM. RathmellW.K. NoushmehrH. SaggioroF.P. TirapelliD.P.C. JuniorC.G.C. MenteE.D. SilvaO.C. TrevisanF.A. KangK.J. AhnK.S. GiamaN.H. MoserC.D. GiordanoT.J. VincoM. WellingT.H. CrainD. CurleyE. GardnerJ. MalleryD. MorrisS. PaulauskisJ. PennyR. SheltonC. SheltonT. KelleyR. ParkJ-W. ChandanV.S. RobertsL.R. BatheO.F. HagedornC.H. AumanJ.T. O’BrienD.R. KocherJ-P.A. JonesC.D. MieczkowskiP.A. PerouC.M. SkellyT. TanD. VeluvoluU. BaluS. BodenheimerT. HoyleA.P. JefferysS.R. MengS. MoseL.E. ShiY. SimonsJ.V. SolowayM.G. RoachJ. HoadleyK.A. BaylinS.B. ShenH. HinoueT. BootwallaM.S. Van Den BergD.J. WeisenbergerD.J. LaiP.H. HolbrookA. BerriosM. LairdP.W. Comprehensive and integrative genomic characterization of hepatocellular carcinoma.Cell2017169713271341.e2310.1016/j.cell.2017.05.04628622513
     [Google Scholar]
  25. FornerA. ReigM. BruixJ. Hepatocellular carcinoma.Lancet2018391101271301131410.1016/S0140‑6736(18)30010‑229307467
     [Google Scholar]
  26. WuY. LiuZ. XuX. Molecular subtyping of hepatocellular carcinoma: A step toward precision medicine.Cancer Commun.2020401268169310.1002/cac2.1211533290597
     [Google Scholar]
  27. XueR. ChenL. ZhangC. FujitaM. LiR. YanS.M. OngC.K. LiaoX. GaoQ. SasagawaS. LiY. WangJ. GuoH. HuangQ.T. ZhongQ. TanJ. QiL. GongW. HongZ. LiM. ZhaoJ. PengT. LuY. LimK.H.T. BootA. OnoA. ChayamaK. ZhangZ. RozenS.G. TehB.T. WangX.W. NakagawaH. ZengM.S. BaiF. ZhangN. Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes.Cancer Cell2019356932947.e810.1016/j.ccell.2019.04.00731130341
     [Google Scholar]
  28. TotokiY. TatsunoK. CovingtonK.R. UedaH. CreightonC.J. KatoM. TsujiS. DonehowerL.A. SlagleB.L. NakamuraH. YamamotoS. ShinbrotE. HamaN. LehmkuhlM. HosodaF. AraiY. WalkerK. DahdouliM. GotohK. NagaeG. GingrasM.C. MuznyD.M. OjimaH. ShimadaK. MidorikawaY. GossJ.A. CottonR. HayashiA. ShibaharaJ. IshikawaS. GuiteauJ. TanakaM. UrushidateT. OhashiS. OkadaN. DoddapaneniH. WangM. ZhuY. DinhH. OkusakaT. KokudoN. KosugeT. TakayamaT. FukayamaM. GibbsR.A. WheelerD.A. AburataniH. ShibataT. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes.Nat. Genet.201446121267127310.1038/ng.312625362482
     [Google Scholar]
  29. El-SeragH.B. RudolphK.L. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis.Gastroenterology200713272557257610.1053/j.gastro.2007.04.06117570226
     [Google Scholar]
  30. WanJ.C.M. MassieC. Garcia-CorbachoJ. MouliereF. BrentonJ.D. CaldasC. PaceyS. BairdR. RosenfeldN. Liquid biopsies come of age: Towards implementation of circulating tumour DNA.Nat. Rev. Cancer201717422323810.1038/nrc.2017.728233803
     [Google Scholar]
  31. YangJ.C. HuJ.J. LiY.X. LuoW. LiuJ.Z. YeD.W. Clinical applications of liquid biopsy in hepatocellular carcinoma.Front. Oncol.20221278182010.3389/fonc.2022.78182035211399
     [Google Scholar]
  32. FuY. YangZ. HuZ. YangZ. PanY. ChenJ. WangJ. HuD. ZhouZ. XuL. ChenM. ZhangY. Preoperative serum ctDNA predicts early hepatocellular carcinoma recurrence and response to systemic therapies.Hepatol. Int.202216486887810.1007/s12072‑022‑10348‑135674872
     [Google Scholar]
  33. QadeerM.A. AbbasZ. AmjadS. ShahidB. AltafA. SiyalM. Des-gamma-carboxy prothrombin and alpha-fetoprotein levels as biomarkers for hepatocellular carcinoma and their correlation with radiological characteristics.World J. Gastrointest. Pathophysiol.20241519089310.4291/wjgp.v15.i1.9089338682024
     [Google Scholar]
  34. ParikhN.D. MehtaA.S. SingalA.G. BlockT. MarreroJ.A. LokA.S. Biomarkers for the early detection of hepatocellular carcinoma.Cancer Epidemiol. Biomarkers Prev.202029122495250310.1158/1055‑9965.EPI‑20‑000532238405
     [Google Scholar]
  35. FinnR.S. QinS. IkedaM. GalleP.R. DucreuxM. KimT.Y. KudoM. BrederV. MerleP. KasebA.O. LiD. VerretW. XuD.Z. HernandezS. LiuJ. HuangC. MullaS. WangY. LimH.Y. ZhuA.X. ChengA.L. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.N. Engl. J. Med.2020382201894190510.1056/NEJMoa191574532402160
     [Google Scholar]
  36. LlovetJ.M. VillanuevaA. LachenmayerA. FinnR.S. Advances in targeted therapies for hepatocellular carcinoma in the genomic era.Nat. Rev. Clin. Oncol.201512740842410.1038/nrclinonc.2015.10326054909
     [Google Scholar]
  37. WongM.C.S. JiangJ.Y. GogginsW.B. LiangM. FangY. FungF.D.H. LeungC. WangH.H.X. WongG.L.H. WongV.W.S. ChanH.L.Y. International incidence and mortality trends of liver cancer: A global profile.Sci. Rep.2017714584610.1038/srep4584628361988
     [Google Scholar]
  38. DietrichC.F. NolsøeC.P. BarrR.G. BerzigottiA. BurnsP.N. CantisaniV. ChammasM.C. ChaubalN. ChoiB.I. ClevertD.A. CuiX. DongY. D’OnofrioM. FowlkesJ.B. GiljaO.H. HuangP. IgneeA. JenssenC. KonoY. KudoM. LassauN. LeeW.J. LeeJ.Y. LiangP. LimA. LyshchikA. MeloniM.F. CorreasJ.M. MinamiY. MoriyasuF. NicolauC. PiscagliaF. SaftoiuA. SidhuP.S. SporeaI. TorzilliG. XieX. ZhengR. Guidelines and good clinical practice recommendations for Contrast Enhanced Ultrasound (CEUS) in the liver – Update 2020 – WFUMB in cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS.Ultraschall Med.202041556258510.1055/a‑1177‑053032707595
     [Google Scholar]
  39. De StefanoF. ChaconE. TurciosL. MartiF. GedalyR. Novel biomarkers in hepatocellular carcinoma.Dig. Liver Dis.201850111115112310.1016/j.dld.2018.08.01930217732
     [Google Scholar]
  40. AyoubW.S. SteggerdaJ. YangJ.D. KuoA. SundaramV. LuS.C. Current status of hepatocellular carcinoma detection: Screening strategies and novel biomarkers.Ther. Adv. Med. Oncol.201911175883591986912010.1177/175883591986912031523283
     [Google Scholar]
  41. AttiaA.M. Rezaee-ZavarehM.S. HwangS.Y. KimN. AdetyanH. YaldaT. ChenP.J. KoltsovaE.K. YangJ.D. Novel biomarkers for early detection of hepatocellular carcinoma.Diagnostics20241420227810.3390/diagnostics1420227839451600
     [Google Scholar]
  42. BardolT. PageauxG.P. AssenatE. Alix-PanabièresC. Circulating tumor DNA clinical applications in hepatocellular carcinoma: Current trends and future perspectives.Clin. Chem.2024701334810.1093/clinchem/hvad16837962158
     [Google Scholar]
  43. YeQ. LingS. ZhengS. XuX. Liquid biopsy in hepatocellular carcinoma: Circulating tumor cells and circulating tumor DNA.Mol. Cancer201918111410.1186/s12943‑019‑1043‑x31269959
     [Google Scholar]
  44. ZhuQ. XieJ. MeiW. ZengC. Methylated circulating tumor DNA in hepatocellular carcinoma: A comprehensive analysis of biomarker potential and clinical implications.Cancer Treat. Rev.202412810276310.1016/j.ctrv.2024.10276338763055
     [Google Scholar]
  45. MallelaV.R. RajtmajerováM. TrailinA. LiškaV. HemminkiK. AmbrozkiewiczF. miRNA and lncRNA as potential tissue biomarkers in hepatocellular carcinoma.Noncoding RNA Res.202491243210.1016/j.ncrna.2023.10.01038075204
     [Google Scholar]
  46. WongC.M. TsangF.H.C. NgI.O.L. Non-coding RNAs in hepatocellular carcinoma: Molecular functions and pathological implications.Nat. Rev. Gastroenterol. Hepatol.201815313715110.1038/nrgastro.2017.16929317776
     [Google Scholar]
  47. FattahiM. RahdanF. ShaterabadiD. Zamani SaniM. AlizadehM. KhatamiS.H. Taheri-AnganehM. MovahedpourA. GhasemiH. MicroRNA biosensors for the detection of liver cancer.Clin. Chim. Acta202455411779610.1016/j.cca.2024.11779638272250
     [Google Scholar]
  48. TangS. LiuH. ChenP. HeJ. ChenH. ChenJ. LiuY. Prognostic value of AFP-L3 and Des-γ-carboxy prothrombin in advanced primary liver cancer treated with Sorafenib and transarterial chemoembolization.Am. J. Transl. Res.20241695004501010.62347/PMYP440439398579
     [Google Scholar]
  49. ShaM. CaoJ. XiaQ. Incorporating AFP-L3 and DCP in selecting patients with hepatocellular carcinoma for liver transplantation: What are the optimal criteria?J. Hepatol.2024804e171e17210.1016/j.jhep.2023.09.03437821020
     [Google Scholar]
  50. LuoX. HeX. ZhangX. ZhaoX. ZhangY. ShiY. HuaS. Hepatocellular carcinoma: Signaling pathways, targeted therapy, and immunotherapy.MedComm202452e47410.1002/mco2.47438318160
     [Google Scholar]
  51. QiuY. CheB. ZhangW. ZhangA.V. GeJ. DuD. LiJ. PengX. ShaoJ. The ubiquitin-like protein FAT10 in hepatocellular carcinoma cells limits the efficacy of anti-VEGF therapy.J. Adv. Res.2024599710910.1016/j.jare.2023.06.00637328057
     [Google Scholar]
  52. LeeT.K.W. GuanX.Y. MaS. Cancer stem cells in hepatocellular carcinoma - From origin to clinical implications.Nat. Rev. Gastroenterol. Hepatol.2022191264410.1038/s41575‑021‑00508‑334504325
     [Google Scholar]
  53. MansurA. VrionisA. CharlesJ.P. HancelK. PanagidesJ.C. MoloudiF. IqbalS. DayeD. The role of artificial intelligence in the detection and implementation of biomarkers for hepatocellular carcinoma: Outlook and opportunities.Cancers20231511292810.3390/cancers1511292837296890
     [Google Scholar]
  54. GongX.Q. LiuN. TaoY.Y. LiL. LiZ.M. YangL. ZhangX.M. Radiomics models based on multisequence MRI for predicting PD-1/PD-L1 expression in hepatocellular carcinoma.Sci. Rep.2023131771010.1038/s41598‑023‑34763‑y37173350
     [Google Scholar]
  55. KucukkayaA.S. ZeeviT. ChaiN.X. RajuR. HaiderS.P. ElbananM. Petukhova-GreensteinA. LinM. OnofreyJ. NowakM. CooperK. ThomasE. SantanaJ. GebauerB. MulliganD. StaibL. BatraR. ChapiroJ. Predicting tumor recurrence on baseline MR imaging in patients with early-stage hepatocellular carcinoma using deep machine learning.Sci. Rep.2023131757910.1038/s41598‑023‑34439‑737165035
     [Google Scholar]
  56. FengS. WangJ. WangL. QiuQ. ChenD. SuH. LiX. XiaoY. LinC. Current status and analysis of machine learning in hepatocellular carcinoma.J. Clin. Transl. Hepatol.202300000000010.14218/JCTH.2022.00077S37577233
     [Google Scholar]
  57. ShinkawaH. IshizawaT. Artificial intelligence-based technology for enhancing the quality of simulation, navigation, and outcome prediction for hepatectomy.Artif. Intell. Surg.202331697910.20517/ais.2022.37
     [Google Scholar]
  58. AgarwalS. YadavA.S. DineshV. VatsavK.S.S. PrakashK.S.S. JaiswalS. By artificial intelligence algorithms and machine learning models to diagnosis cancer.Mater. Today Proc.2023802969297510.1016/j.matpr.2021.07.088
     [Google Scholar]
  59. ShenX. WuJ. SuJ. YaoZ. HuangW. ZhangL. JiangY. YuW. LiZ. Revisiting artificial intelligence diagnosis of hepatocellular carcinoma with DIKWH framework.Front. Genet.202314100448110.3389/fgene.2023.100448137007970
     [Google Scholar]
  60. JiG.W. ZhuF.P. XuQ. WangK. WuM.Y. TangW.W. LiX.C. WangX.H. Machine-learning analysis of contrast-enhanced CT radiomics predicts recurrence of hepatocellular carcinoma after resection: A multi-institutional study.EBioMedicine20195015616510.1016/j.ebiom.2019.10.05731735556
     [Google Scholar]
  61. SongD. WangY. WangW. WangY. CaiJ. ZhuK. LvM. GaoQ. ZhouJ. FanJ. RaoS. WangM. WangX. Using deep learning to predict microvascular invasion in hepatocellular carcinoma based on dynamic contrast-enhanced MRI combined with clinical parameters.J. Cancer Res. Clin. Oncol.2021147123757376710.1007/s00432‑021‑03617‑333839938
     [Google Scholar]
  62. ZhangY. LvX. QiuJ. ZhangB. ZhangL. FangJ. LiM. ChenL. WangF. LiuS. ZhangS. Deep learning with 3D convolutional neural network for noninvasive prediction of microvascular invasion in hepatocellular carcinoma.J. Magn. Reson. Imaging202154113414310.1002/jmri.2753833559293
     [Google Scholar]
  63. JiangY.Q. CaoS.E. CaoS. ChenJ.N. WangG.Y. ShiW.Q. DengY.N. ChengN. MaK. ZengK.N. YanX.J. YangH.Z. HuanW.J. TangW.M. ZhengY. ShaoC.K. WangJ. YangY. ChenG.H. Preoperative identification of microvascular invasion in hepatocellular carcinoma by XGBoost and deep learning.J. Cancer Res. Clin. Oncol.2021147382183310.1007/s00432‑020‑03366‑932852634
     [Google Scholar]
  64. WangW. Deep learning-based radiomics models for early recurrence prediction of hepatocellular carcinoma with multi-phase CT images and clinical data.2019 41st Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC)Berlin, Germany; 2019; pp. 4881-4884.10.1109/EMBC.2019.8856356
     [Google Scholar]
  65. MalikS. DasR. ThongtanT. ThompsonK. DboukN. AI in hepatology: Revolutionizing the diagnosis and management of liver disease.J. Clin. Med.20241324783310.3390/jcm1324783339768756
     [Google Scholar]
  66. KohB. DanpanichkulP. WangM. TanD.J.H. NgC.H. Application of artificial intelligence in the diagnosis of hepatocellular carcinoma.eGastroenterology202312e10000210.1136/egastro‑2023‑10000239944000
     [Google Scholar]
  67. CastaldoA. De LuciaD.R. PontilloG. GattiM. CocozzaS. UggaL. CuocoloR. State of the art in artificial intelligence and radiomics in hepatocellular carcinoma.Diagnostics2021117119410.3390/diagnostics1107119434209197
     [Google Scholar]
  68. Artificial intelligence in healthcare.2021Available from: https://share.google/FupNdIL5tS6vjee84
  69. Clinical decision support system.2020Available from: https://en.wikipedia.org/wiki/Clinical_decision_support_system
    [Google Scholar]
  70. NordkildS.B. AhlbornL.B. YdeC.W. KuglerJ.M. KlubienJ. AkdagD. WillemoeG.L. NielsenS.D. PommergaardH.C. Prognostic genomic alterations in patients undergoing liver resection for hepatocellular carcinoma.Mol. Biol. Rep.202451145010.1007/s11033‑024‑09396‑738536546
     [Google Scholar]
  71. LurjeI. CziganyZ. BednarschJ. RoderburgC. IsfortP. NeumannU.P. LurjeG. Treatment strategies for hepatocellular carcinoma - A multidisciplinary approach.Int. J. Mol. Sci.2019206146510.3390/ijms2006146530909504
     [Google Scholar]
  72. PodlasekA. AbdullaM. BroeringD. BzeiziK. Recent advances in locoregional therapy of hepatocellular carcinoma.Cancers20231513334710.3390/cancers1513334737444457
     [Google Scholar]
  73. YaoF.Y. MehtaN. FlemmingJ. DodgeJ. HameedB. FixO. HiroseR. FidelmanN. KerlanR.K. RobertsJ.P. Downstaging of hepatocellular cancer before liver transplant: Long‐term outcome compared to tumors within Milan criteria.Hepatology20156161968197710.1002/hep.2775225689978
     [Google Scholar]
  74. ShehtaA. MedhatM. FaroukA. MonierA. SaidR. SalahT. FouadA. AliM.A. Liver resection for hepatocellular carcinoma in elderly patients: Does age matter?BMC Surg.202424124810.1186/s12893‑024‑02528‑739237941
     [Google Scholar]
  75. LencioniR. LlovetJ. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.Semin Liver Dis2010301526010.1055/s‑0030‑1247132
     [Google Scholar]
  76. PompiliM. SavianoA. de MatthaeisN. CucchettiA. ArditoF. FedericoB. BrunelloF. PinnaA.D. GiorgioA. GiuliniS.M. De SioI. TorzilliG. FornariF. CapussottiL. GuglielmiA. PiscagliaF. AldrighettiL. CaturelliE. CaliseF. NuzzoG. RapacciniG.L. GiulianteF. Long-term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ⩽3cm. Results of a multicenter Italian survey.J. Hepatol.2013591899710.1016/j.jhep.2013.03.00923523578
     [Google Scholar]
  77. DahmF. GeorgievP. ClavienP.A. Small-for-size syndrome after partial liver transplantation: Definition, mechanisms of disease and clinical implications.Am. J. Transplant.20055112605261010.1111/j.1600‑6143.2005.01081.x16212618
     [Google Scholar]
  78. ClavienP.A. PetrowskyH. DeOliveiraM.L. GrafR. Strategies for safer liver surgery and partial liver transplantation.N. Engl. J. Med.2007356151545155910.1056/NEJMra06515617429086
     [Google Scholar]
  79. VautheyJ.N. DixonE. AbdallaE.K. HeltonW.S. PawlikT.M. TaouliB. BrouquetA. AdamsR.B. Pretreatment assessment of hepatocellular carcinoma: Expert consensus statement.HPB201012528929910.1111/j.1477‑2574.2010.00181.x20590901
     [Google Scholar]
  80. AbdallaE.K. DenysA. ChevalierP. NemrR.A. VautheyJ.N. Total and segmental liver volume variations: Implications for liver surgery.Surgery2004135440441010.1016/j.surg.2003.08.02415041964
     [Google Scholar]
  81. KinoshitaH. SakaiK. HirohashiK. IgawaS. YamasakiO. KuboS. Preoperative portal vein embolization for hepatocellular carcinoma.World J. Surg.198610580380810.1007/BF016552443022488
     [Google Scholar]
  82. FargesO. BelghitiJ. KianmaneshR. Marc RegimbeauJ. SantoroR. VilgrainV. DenysA. SauvanetA. Portal vein embolization before right hepatectomy: Prospective clinical trial.Ann. Surg.2003237220821710.1097/01.SLA.0000048447.16651.7B12560779
     [Google Scholar]
  83. OrcuttS.T. AnayaD.A. Liver resection and surgical strategies for management of primary liver cancer.Cancer Contr.2018251107327481774462110.1177/107327481774462129327594
     [Google Scholar]
  84. VitaleA. BurraP. FrigoA.C. TrevisaniF. FarinatiF. SpolveratoG. VolkM. GianniniE.G. CiccareseF. PiscagliaF. RapacciniG.L. Di MarcoM. CaturelliE. ZoliM. BorzioF. CabibboG. FelderM. GasbarriniA. SaccoR. FoschiF.G. MissaleG. MoriscoF. Svegliati BaroniG. VirdoneR. CilloU. Survival benefit of liver resection for patients with hepatocellular carcinoma across different Barcelona Clinic Liver Cancer stages: A multicentre study.J. Hepatol.201562361762410.1016/j.jhep.2014.10.03725450706
     [Google Scholar]
  85. IshizawaT. HasegawaK. AokiT. TakahashiM. InoueY. SanoK. ImamuraH. SugawaraY. KokudoN. MakuuchiM. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma.Gastroenterology200813471908191610.1053/j.gastro.2008.02.09118549877
     [Google Scholar]
  86. YinL. LiH. LiA.J. LauW.Y. PanZ. LaiE.C.H. WuM. ZhouW.P. Partial hepatectomy vs. transcatheter arterial chemoembolization for resectable multiple hepatocellular carcinoma beyond Milan criteria: A RCT.J. Hepatol.2014611828810.1016/j.jhep.2014.03.01224650695
     [Google Scholar]
  87. LeeJ.M. JangB.K. LeeY.J. ChoiW.Y. ChoiS.M. ChungW.J. HwangJ.S. KangK.J. KimY.H. ChauhanA.K. ParkS.Y. TakW.Y. KweonY.O. KimB.S. LeeC.H. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.Clin. Mol. Hepatol.201622116016710.3350/cmh.2016.22.1.16027044767
     [Google Scholar]
  88. BanD. ShimadaK. YamamotoY. NaraS. EsakiM. SakamotoY. KosugeT. Efficacy of a hepatectomy and a tumor thrombectomy for hepatocellular carcinoma with tumor thrombus extending to the main portal vein.J. Gastrointest. Surg.200913111921192810.1007/s11605‑009‑0998‑019727969
     [Google Scholar]
  89. BruixJ. ShermanM. Management of hepatocellular carcinoma: An update.Hepatology20115331020102210.1002/hep.2419921374666
     [Google Scholar]
  90. JooI. LeeJ.M. Recent advances in the imaging diagnosis of hepatocellular carcinoma: Value of gadoxetic acid-enhanced MRI.Liver Cancer201651678710.1159/00036775026989660
     [Google Scholar]
  91. GalleP.R. FornerA. LlovetJ.M. MazzaferroV. PiscagliaF. RaoulJ.L. SchirmacherP. VilgrainV. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.J. Hepatol.201869118223610.1016/j.jhep.2018.03.01929628281
     [Google Scholar]
  92. LlovetJ.M. BruixJ. Novel advancements in the management of hepatocellular carcinoma in 2008.J. Hepatol.200848Suppl. 1S20S3710.1016/j.jhep.2008.01.02218304676
     [Google Scholar]
  93. YaoF.Y. FerrellL. BassN.M. WatsonJ.J. BacchettiP. VenookA. AscherN.L. RobertsJ.P. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival.Hepatology20013361394140310.1053/jhep.2001.2456311391528
     [Google Scholar]
  94. MazzaferroV. SpositoC. ZhouJ. PinnaA.D. De CarlisL. FanJ. CesconM. Di SandroS. Yi-fengH. LauterioA. BonginiM. CucchettiA. Metroticket 2.0 model for analysis of competing risks of death after liver transplantation for hepatocellular carcinoma.Gastroenterology2018154112813910.1053/j.gastro.2017.09.02528989060
     [Google Scholar]
  95. SalemR. LewandowskiR.J. MulcahyM.F. RiazA. RyuR.K. IbrahimS. AtassiB. BakerT. GatesV. MillerF.H. SatoK.T. WangE. GuptaR. BensonA.B. NewmanS.B. OmaryR.A. AbecassisM. KulikL. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: A comprehensive report of long-term outcomes.Gastroenterology20101381526410.1053/j.gastro.2009.09.00619766639
     [Google Scholar]
  96. JiangC. FengQ. ZhangZ. QiangZ. DuA. XuL. LiJ. Radiofrequency ablation versus laparoscopic hepatectomy for hepatocellular carcinoma: A systematic review and meta-analysis.World J. Surg. Oncol.202422118810.1186/s12957‑024‑03473‑839049043
     [Google Scholar]
  97. LuoJ. GuoR.P. LaiE.C.H. ZhangY.J. LauW.Y. ChenM.S. ShiM. Transarterial chemoembolization for unresectable hepatocellular carcinoma with portal vein tumor thrombosis: A prospective comparative study.Ann. Surg. Oncol.201118241342010.1245/s10434‑010‑1321‑820839057
     [Google Scholar]
  98. HongY.M. Neutrophil count predicts the complete response after transarterial chemoembolization related to favorable outcome in hepatocellular carcinoma.Eur. J. Gastroenterol. Hepatol.2025371949910.1097/MEG.000000000000287339445526
     [Google Scholar]
  99. VoglT. Nour-EldinN.-E. HammerstinglR. PanahiB. NaguibN. Microwave ablation (MWA): Basics, technique and results in primary and metastatic liver neoplasms – Review article.Rofo2017189111055106610.1055/s‑0043‑117410
     [Google Scholar]
  100. ChaturvediA. K. Radiofrequency and microwave thermal ablation in cancer therapy and the role of hydrodissection.The Application of Heat in Oncology: Principles and PracticeWiley202310.1002/9781119799627.ch23
     [Google Scholar]
  101. ChengA.L. HsuC. ChanS.L. ChooS.P. KudoM. Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma.J. Hepatol.202072230731910.1016/j.jhep.2019.09.02531954494
     [Google Scholar]
  102. El-KhoueiryA.B. SangroB. YauT. CrocenziT.S. KudoM. HsuC. KimT.Y. ChooS.P. TrojanJ. WellingT.H. MeyerT. KangY.K. YeoW. ChopraA. AndersonJ. dela CruzC. LangL. NeelyJ. TangH. DastaniH.B. MeleroI. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial.Lancet2017389100882492250210.1016/S0140‑6736(17)31046‑228434648
     [Google Scholar]
  103. RomanziA. Angiopoietin-2 and the vascular endothelial growth factor promote migration and invasion in hepatocellular carcinoma- and intrahepatic cholangiocarcinoma-derived spheroids.Biomedicines20241218710.3390/biomedicines12010087
     [Google Scholar]
  104. ChenY.H. TsaiC.H. ChenY.Y. WangC.C. WangJ.H. HungC.H. KuoY.H. Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma.BMC Cancer202323181010.1186/s12885‑023‑11298‑z37644388
     [Google Scholar]
  105. FoersterF. GairingS.J. IlyasS.I. GalleP.R. Emerging immunotherapy for HCC: A guide for hepatologists.Hepatology20227561604162610.1002/hep.3244735253934
     [Google Scholar]
  106. FoersterF. GalleP.R. The current landscape of clinical trials for systemic treatment of HCC.Cancers2021138196210.3390/cancers1308196233921731
     [Google Scholar]
  107. KudoM. Scientific rationale for combined immunotherapy with PD-1/PD-L1 antibodies and vegf inhibitors in advanced hepatocellular carcinoma.Cancers2020125108910.3390/cancers1205108932349374
     [Google Scholar]
  108. HaoL. LiS. YeF. WangH. ZhongY. ZhangX. HuX. HuangX. The current status and future of targeted-immune combination for hepatocellular carcinoma.Front. Immunol.202415141896510.3389/fimmu.2024.141896539161764
     [Google Scholar]
  109. MoriguchiM. KataokaS. ItohY. Evolution of systemic treatment for hepatocellular carcinoma: Changing treatment strategies and concepts.Cancers20241613238710.3390/cancers1613238739001448
     [Google Scholar]
  110. CalderaroJ. ZiolM. ParadisV. Zucman-RossiJ. Molecular and histological correlations in liver cancer.J. Hepatol.201971361663010.1016/j.jhep.2019.06.00131195064
     [Google Scholar]
  111. YanY. SiZ. ChunC. Chao-qunP. KeM. DongZ. LiW. Multiphase MRI‐based radiomics for predicting histological grade of hepatocellular carcinoma.J. Magn. Reson. Imaging2024605jmri.2928910.1002/jmri.2928938344854
     [Google Scholar]
  112. AddissoukyT.A. SayedI.E.T.E. AliM.M.A. WangY. BazA.E. KhalilA.A. ElarabanyN. Latest advances in hepatocellular carcinoma management and prevention through advanced technologies.Egyptian Liver Journal2024141210.1186/s43066‑023‑00306‑3
     [Google Scholar]
  113. DykmanL. KhlebtsovB. KhlebtsovN. Drug delivery using gold nanoparticles.Adv. Drug Deliv. Rev.202521611548110.1016/j.addr.2024.11548139617254
     [Google Scholar]
  114. TangB. LinX. ZouF. FanY. LiD. ZhouJ. ChenW. WangX. In situ synthesis of gold nanoparticles on cotton fabric for multifunctional applications.Cellulose201724104547456010.1007/s10570‑017‑1413‑8
     [Google Scholar]
  115. KlopfleischR. GruberA.D. Transcriptome and proteome research in veterinary science: What is possible and what questions can be asked?ScientificWorldJournal2012201211410.1100/2012/25496222262952
     [Google Scholar]
  116. BrownZ.J. TsilimigrasD.I. RuffS.M. MohseniA. KamelI.R. CloydJ.M. PawlikT.M. Management of hepatocellular carcinoma.JAMA Surg.2023158441042010.1001/jamasurg.2022.798936790767
     [Google Scholar]
  117. TosoC. MenthaG. KnetemanN.M. MajnoP. The place of downstaging for hepatocellular carcinoma.J. Hepatol.201052693093610.1016/j.jhep.2009.12.03220385428
     [Google Scholar]
  118. PelizzaroF. GambatoM. GringeriE. VitaleA. CilloU. FarinatiF. BurraP. RussoF.P. Management of hepatocellular carcinoma recurrence after liver transplantation.Cancers20211319488210.3390/cancers1319488234638365
     [Google Scholar]
  119. HoK. ChanA. Liver transplantation for hepatocellular carcinoma: Current status in Hong Kong, China.Hepatobiliary Pancreat. Dis. Int.2025241454910.1016/j.hbpd.2024.09.00539307663
     [Google Scholar]
  120. CitoresM.J. LucenaJ.L. FuenteS. Cuervas-MonsV. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation.World J. Hepatol.2019111506410.4254/wjh.v11.i1.5030705718
     [Google Scholar]
  121. LencioniR. Loco‐regional treatment of hepatocellular carcinoma.Hepatology201052276277310.1002/hep.2372520564355
     [Google Scholar]
  122. MassironiS. PillaL. ElveviA. LongariniR. RossiR.E. BidoliP. InvernizziP. New and emerging systemic therapeutic options for advanced cholangiocarcinoma.Cells20209368810.3390/cells903068832168869
     [Google Scholar]
  123. AlossK. HamarP. Recent preclinical and clinical progress in liposomal doxorubicin.Pharmaceutics202315389310.3390/pharmaceutics1503089336986754
     [Google Scholar]
  124. TaghizadehS. AlimardaniV. RoudbaliP.L. GhasemiY. KavianiE. Gold nanoparticles application in liver cancer.Photodiagn. Photodyn. Ther.20192538940010.1016/j.pdpdt.2019.01.02730684673
     [Google Scholar]
  125. NguangS.H. WuC.K. LiangC.M. TaiW.C. YangS.C. KuM.K. YuanL.T. WangJ.W. TsengK.L. HungT.H. HsuP.I. WuD.C. ChuahS.K. HsuC.N. Treatment and cost of hepatocellular carcinoma: A population-based cohort study in Taiwan.Int. J. Environ. Res. Public Health20181512265510.3390/ijerph1512265530486324
     [Google Scholar]
  126. YuenS.C. AmaefuleA.Q. KimH.H. OwooB.V. GormanE.F. MattinglyT.J. A systematic review of cost-effectiveness analyses for hepatocellular carcinoma treatment.PharmacoEconom. Open20226191910.1007/s41669‑021‑00298‑z34427897
     [Google Scholar]
  127. LalL.S. AlyA. LeL.B. PeckousS. SealB. TeitelbaumA. Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims study.Cancer Rep.202255e150410.1002/cnr2.150434494389
     [Google Scholar]
  128. CallendretB. WalkerC.M. Will there be a vaccine to protect against the hepatitis C virus?Gastroenterology201214261384138710.1053/j.gastro.2012.02.01022537447
     [Google Scholar]
  129. Sorafenib.2025Available from: https://share.google/ e4eCyBGT55giBhmwM.
  130. SadrinasabS. SaketS. PourmohammadiN. KhosraviF. FakhrM.S. Modern therapeutic approaches for hepatic tumors: Progress, limitations, and future directions.Discover Oncology202516195910.1007/s12672‑025‑02773‑z40445470
     [Google Scholar]
  131. LünseS. HeideckeC-D. ParteckeL.I. Current topics and perspectives in surgical management of hepatocellular carcinoma.Hepatocellular CarcinomaCodon citations Brisbane201910.15586/hepatocellularcarcinoma.2019.ch6
     [Google Scholar]
  132. LazzaroA. HartshornK.L. A Comprehensive Narrative Review on the History, Current Landscape, and Future Directions of Hepatocellular Carcinoma (HCC) Systemic Therapy.Cancers2023159250610.3390/cancers1509250637173972
     [Google Scholar]
  133. LiC. LuB. DengB. New insights into the diagnosis and treatment of hepatocellular carcinoma.Biomedicines202513124410.3390/biomedicines13051244
     [Google Scholar]
  134. Méndez-SánchezN. Valencia-RodríguezA. Coronel-CastilloC.E. QiX. Narrative review of hepatocellular carcinoma: From molecular bases to therapeutic approach.Dig. Med. Res.2021401510.21037/dmr‑20‑116
     [Google Scholar]
  135. UyumazturkB. KianiA. RajpurkarP. WangA. BallR.L. GaoR. YuY. JonesE. LanglotzC.P. MartinB. BerryG.J. OzawaM.G. HazardF.K. BrownR.A. ChenS.B. WoodM. AllardL.S. YlaganL. NgA.Y. ShenJ. Deep learning for the digital pathologic diagnosis of cholangiocarcinoma and hepatocellular carcinoma: Evaluating the impact of a web-based diagnostic assistant.arXiv2019
     [Google Scholar]
/content/journals/cis/10.2174/012210299X413855251206110649
Loading
Advances in Hepatocellular Carcinoma Management: Diagnostic Innovations and Treatment Strategies
Curr. Indian Sci. 4, E2210299X413855 (2026); https://doi.org/10.2174/012210299X413855251206110649
/content/journals/cis/10.2174/012210299X413855251206110649
/content/journals/cis/10.2174/012210299X413855251206110649
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): Cancer treatment; Genomic; Hepatocellular carcinoma; Immunotherapy; Liver transplantation; Surgery; Tumors

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test